Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. (PACB) on March 24, 2025. The filing discloses the appointment of a new Chief Financial Officer and the conclusion of the interim CFO role held by the CEO.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Jim R. Gibson as Chief Financial Officer and Principal Financial Officer, effective March 31, 2025. Consequently, Christian Henry, President and CEO, will cease serving as interim CFO upon Mr. Gibson's start date.
Compensation and Management Commentary
Mr. Gibson's compensation package includes the following terms:
- Base Salary: $500,000 annually.
- Target Bonus: 55% of base salary, subject to performance goals.
- Stock Options: 2,000,000 shares vesting 25% on the first anniversary and monthly thereafter.
- Restricted Stock Units (RSUs): 1,000,000 shares vesting 25% annually.
- Severance and Change in Control: Includes 12 months of base salary and COBRA coverage for termination without cause or resignation for good reason. In the event of a change in control, benefits include the annualized target bonus and 100% acceleration of unvested equity awards.
Mr. Gibson brings prior experience as CFO of Sequoia Benefits and Insurance Services, LLC, Willow Innovations, Inc., and as VP of Finance Transformation at GoDaddy, Inc.
Investor Verification Checklist
- Verify the exact start date of Mr. Gibson's employment (anticipated March 31, 2025).
- Review the standard form of change in control and severance agreement filed as Exhibit 10.13 to the March 17, 2025 Form 10-K.
- Confirm the vesting commencement dates for the 2,000,000 stock options and 1,000,000 RSUs.
- Monitor the press release dated March 27, 2025 (Exhibit 99.1) for additional public commentary.